Depression, Bipolar & Mood Disorders • ICD-10-CM F55.2
Laxative abuse
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM F55.2 • 8 Linked .gov / PubMed Citations
•
Governance: Dr. Hannah Lindqvist, MD, PhD (NPI #1457952647)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Laxative abuse Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Depression, Bipolar & Mood Disorders diagnostic criteria (F55.2), workup for Laxative abuse integrates medication response pharmacogenomics [Laxative abuse F55.2] with evidence-graded therapy tailored to TSH & Free in Laxative abuse (F55.2: T4 Rule-Out) response.
- 2 Real-world patient consensus: Federal ICD-10-CM code F55.2 categorizes Laxative abuse under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Workup highlights for Laxative abuse (F55.2): medication response pharmacogenomics [Laxative abuse F55.2].
- 4 Top reported side effects / signs: Follow-up benchmark in Laxative abuse: maintaining TSH & Free in Laxative abuse (F55.2: T4 Rule-Out) within TSH 0.8 – 2.5 mIU/L (F55.2).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Laxative abuse
What Is Laxative abuse?
Under Depression, Bipolar & Mood Disorders diagnostic criteria (F55.2), workup for Laxative abuse integrates medication response pharmacogenomics [Laxative abuse F55.2] with evidence-graded therapy tailored to TSH & Free in Laxative abuse (F55.2: T4 Rule-Out) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Laxative abuse (code F55.2) is dopamine) signaling imbalance [Laxative abuse F55.2], which Depression, Bipolar & Mood Disorders clinicians address while surveilling TSH & Free in Laxative abuse (F55.2: T4 Rule-Out) (TSH 0.8 – 2.5 mIU/L (F55.2)).
Common Symptoms & Clinical Signs
- • Presentation of Laxative abuse (F55.2): loss of interest in Laxative abuse (F55.2: or pleasure in)
- • Secondary Laxative abuse clinical sign: persistent low mood, in Laxative abuse (F55.2: emotional flatness, or)
- • Symptom flares in Laxative abuse correlating with TSH & Free in Laxative abuse (F55.2: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F55.2)
- • Functional depression & mood impact requiring medication response pharmacogenomics [Laxative abuse F55.2] evaluation (F55.2)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Laxative abuse Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F55.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TSH & Free in Laxative abuse (F55.2: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F55.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Laxative abuse (F55.2: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F55.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Laxative abuse (F55.2: Score) | < 4 (clinical remission) (F55.2) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Laxative abuse
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Potassium Phosphates (Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic) Potassium Phosphates • RxCUI 1928569 | Osmotic Laxative | 79% | $2.3400 | $ 176.98 /mo |
| Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Glucose and Sodium Chloride • RxCUI RXN-B03389799 | Osmotic Laxative | 87% | $3.2000 | $ 238.90 /mo |
| Klor-Con (Potassium Chloride) Klor-Con • RxCUI 628953 | Osmotic Laxative | 89% | $0.1181 | $ 13.51 /mo |
| Pokonza (Potassium Chloride) Pokonza • RxCUI 1867544-B15370306 | Osmotic Laxative | 83% | $27.4582 | $ 640.00 /mo |
| Kristalose (Lactulose) Kristalose • RxCUI 1251190 | Osmotic Laxative | 81% | $9.3956 | $ 640.00 /mo |
| Laxative Enteric Coated (Bisacodyl 5mg) Laxative Enteric Coated • RxCUI 308753-B68998404 | Stimulant Laxative | 77% | $0.3586 | $ 34.32 /mo |
| Polyethylene Glycol 3350 and Electrolytes with Orange Flavor Polyethylene Glycol 3350 and Electrolyteswith Orange Flavor • RxCUI RXN-64380767-2966 | Osmotic Laxative | 77% | $0.0185 | $ 9.25 /mo |
| Bisacodyl Laxative, Onelax • RxCUI 308753 | Stimulant Laxative | 86% | $0.3586 | $ 23.02 /mo |
| Womens Laxtive Womens Laxative • RxCUI RXN-69168490-2135 | Stimulant Laxative | 92% | $0.4600 | $ 27.13 /mo |
| Klor-Con/Ef (Potassium Bicarbonate) Klor-Con/Ef • RxCUI RXN-B02455326 | Osmotic Laxative | 94% | $0.8594 | $ 70.38 /mo |
| Potassium Phosphate Potassium Phosphate Generic • RxCUI RXN-70069746-3119 | Osmotic Laxative | 90% | $0.7500 | $ 38.88 /mo |
| Bisacodyl 5mg Laxative Enteric Coated, Laxative • RxCUI RXN-68998404-2150 | Stimulant Laxative | 82% | $0.3586 | $ 23.02 /mo |
| Effer-K 20 Meq Unflavored (Potassium Bicarbonate) Effer-K 20 Meq Unflavored • RxCUI 1111263 | Osmotic Laxative | 87% | $0.5196 | $ 45.91 /mo |
| Lactulose Solution USP, 10 G/15 Ml Lactulose Solution USP, 10 G/15 Ml Generic • RxCUI RXN-64980592-2412 | Osmotic Laxative | 85% | $0.0125 | $ 9.01 /mo |
| Polyethylene Glycol 3350 and Electrolytes - Unflavored Polyethylene Glycol 3350 and Electrolytes - Unflavored Generic • RxCUI 966920 | Osmotic Laxative | 92% | $0.0044 | $ 8.68 /mo |
| Saline Laxative (Sodium Phosphate) Saline Laxative • RxCUI 283100 | Over-the-Counter Clinical Monograph | 86% | $3.1100 | $ 232.42 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Laxative abuse)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Establishing moderators and biosignatures of antidepressant response in clinical: What a 300-Participant Study Found Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC). Journal of psychiatric research • 2016-07-15 • Randomized Controlled Trial | N = 300 | 93/100 | PMID 27038550 ↗ |
| Can This Approach Help? Inside the Latest Research on Lavender oil preparation Silexan is effective in mild-to-moderate major The results for sertraline confirm the assay sensitivity of the trial. European archives of psychiatry and clinical neuroscience • 2025-09-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 38558147 ↗ |
| Can This Approach Help? Inside the Latest Research on Transcranial direct current stimulation using miniaturized devices vs sertraline There were no significant group differences in the rate of side effects. Journal of psychiatric research • 2020-08-15 • Randomized Controlled Trial | N = 45 | 88/100 | PMID 32464489 ↗ |
| Can This Approach Help? Inside the Latest Research on Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Pretreatment reward sensitivity and frontostriatal connectivity may identify patients likely to benefit from bupropion following selective serotonin reuptake inhibitor failures. Biological psychiatry • 2020-10-15 • Randomized Controlled Trial | N = 116 | 88/100 | PMID 32507389 ↗ |
| Can This Approach Help? Inside the Latest Research on Impact of antidepressant treatment on the network structure of neurocognition and Network analysis revealed a pre-treatment relationship between a HSA and decreased phonemic VF among depressed patients, which was no longer present after 8 weeks of antidepressant treatment. Journal of affective disorders • 2024-09-15 • Randomized Controlled Trial | N = 120 | 82/100 | PMID 38823590 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Laxative abuse Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Laxative abuse community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Laxative abuse.